Clinical cornerstone最新文献_第8页

Identification and Treatment of Prediabetes to Prevent Progression to Type 2 Diabetes 糖尿病前期的识别和治疗以防止发展为2型糖尿病

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2009-05-03 DOI: 10.1016/S1098-3597(09)60004-1

Vivian A. Fonseca MD

{"title":"Identification and Treatment of Prediabetes to Prevent Progression to Type 2 Diabetes","authors":"Vivian A. Fonseca MD","doi":"10.1016/S1098-3597(09)60004-1","DOIUrl":"10.1016/S1098-3597(09)60004-1","url":null,"abstract":"<div>Overt type 2 diabetes is usually preceded by a condition known as prediabetes, which is characterized by impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). Both IFG and IGT exhibit elevated glucose levels that are not sufficient to be classified as diabetes but that represent the development of insulin resistance. Achieving glycemic control in patients with prediabetes through lifestyle and pharmacologic interventions can effectively prevent or delay the development of diabetes and its associated complications. The first step, however, is to identify patients at risk. Although patients can be identified with an oral glucose tolerance test (OGTT) or a fasting plasma glucose (FPG) screening, a normal FPG does not preclude an elevated OGTT and, therefore, the presence of prediabetes. For patients who progress to type 2 diabetes, intensive therapy aimed at reducing and maintaining glycosylated hemoglobin (A1C) levels <7% has been shown to reduce the risk of complications. An A1C level ≥7% should signal the need to initiate or change therapy to achieve glycemic goals.</div>","PeriodicalId":80265,"journal":{"name":"Clinical cornerstone","volume":"8 2","pages":"Pages 10-20"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1098-3597(09)60004-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27336952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 54

Future Directions in Insulin Therapy and Treatment of Diabetes Mellitus: A Critical Comment 胰岛素治疗和治疗糖尿病的未来发展方向:综述

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2009-05-03 DOI: 10.1016/S1098-3597(09)60009-0

Lutz Heinemann PhD

引用次数: 1

CME Test Questions CME考试问题

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2009-05-03 DOI: 10.1016/S1098-3597(09)60010-7

引用次数: 0

Overweight and obesity: Key components of cardiometabolic risk 超重和肥胖:心脏代谢风险的关键组成部分

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2008-04-29 DOI: 10.1016/S1098-3597(07)80026-3

Louis J. Aronne MD (Clinical Professor of Medicine), Kathy K. Isoldi MS, RD, CDE (Coordinator of Clinical Nutrition Services)

{"title":"Overweight and obesity: Key components of cardiometabolic risk","authors":"Louis J. Aronne MD (Clinical Professor of Medicine), Kathy K. Isoldi MS, RD, CDE (Coordinator of Clinical Nutrition Services)","doi":"10.1016/S1098-3597(07)80026-3","DOIUrl":"10.1016/S1098-3597(07)80026-3","url":null,"abstract":"<div>The current obesity epidemic is a major public health concern worldwide, in both developed and developing countries, and in adults and children alike. Obesity confers physical stress on multiple biologic processes and is associated with an increased risk of developing cardiovascular disease, type 2 diabetes mellitus, osteoarthritis, and certain forms of cancer, among other serious diseases. Therefore, it is essential that all health care providers take an active role in addressing the issue of obesity with their patients to reduce their cardiometabolic risks. Indeed, there is a 3-fold increase in the odds that a patient will attempt weight loss if it is recommended by a trusted health care professional. A reduction of only 5% to 10% of body weight improves lipid profiles, insulin sensitivity, and endothelial function, and reduces thrombosis and inflammatory markers. There is evidence, however, that humans are highly sensitive to the availability and nature of food in the environment, which presents a formidable obstacle to achieving lasting weight loss. The National Heart, Lung, and Blood Institute of the National Institutes of Health recommends lifestyle modification as the primary intervention. For individuals who do not respond or for those who also have a weight-related illness, a weight loss medication may need to be added to their treatment plan. While there are few medical options currently available, new compounds for the treatment of obesity are under investigation.</div>","PeriodicalId":80265,"journal":{"name":"Clinical cornerstone","volume":"8 3","pages":"Pages 29-37"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1098-3597(07)80026-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27418323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 58

Reducing cardiometabolic risk through selective antagonism of CB1 receptors 通过选择性拮抗CB1受体降低心脏代谢风险

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2007-12-22 DOI: 10.1016/S1098-3597(07)80012-3

Luc van Gaal MD

{"title":"Reducing cardiometabolic risk through selective antagonism of CB1 receptors","authors":"Luc van Gaal MD","doi":"10.1016/S1098-3597(07)80012-3","DOIUrl":"10.1016/S1098-3597(07)80012-3","url":null,"abstract":"<div>Over the past 15 years, research on the endogenous cannabinoid (CB) system—now usually referred to as the endocannabinoid system (ECS)—has identified the significant effects of the ECS on the regulation of food intake and lipid and glucose metabolism in animals and humans. Endocannabinoids are endogenous lipids capable of binding to endogenous CB1 and CB2 receptors. CB1 receptors are present in the hypothalamic nuclei, which are involved in the control of energy balance and body weight, and in the mesolimbic system, which mediates the motivation to consume palatable food, as well as in adipocytes, the gut, and the liver. In the recent Rimonabant in Obesity (RIO)-Europe study, treatment with the first CB1 receptor antagonist, rimonabant, led to sustained, clinically meaningful weight loss and a reduction in waist circumference. Patients treated with rimonabant also demonstrated statistically significant improvement in high-density lipoprotein cholesterol levels, triglyceride levels, and insulin resistance, as well as a reduced overall prevalence of metabolic syndrome. Results of this and other studies support the role of endocannabinoids in the development and maintenance of obesity. In addition, these findings suggest that CB1 receptor antagonists such as rimonabant may offer a potential new approach to managing obesity and associated cardiometabolic risk factors.</div>","PeriodicalId":80265,"journal":{"name":"Clinical cornerstone","volume":"8 ","pages":"Pages S24-S29"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1098-3597(07)80012-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27058357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Treatment of Diabetes: A Clinical Update on Insulin Trials 糖尿病的治疗:胰岛素试验的临床进展

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2009-05-03 DOI: 10.1016/S1098-3597(09)60005-3

Derek LeRoith MD, PhD

引用次数: 8

Cardiovascular disease and modifiable cardiometabolic risk factors 心血管疾病和可改变的心脏代谢危险因素

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2008-04-29 DOI: 10.1016/S1098-3597(07)80025-1

Christopher P. Cannon MD (Senior Investigator, TIMI Study Group, Associate Professor of Medicine)

{"title":"Cardiovascular disease and modifiable cardiometabolic risk factors","authors":"Christopher P. Cannon MD (Senior Investigator, TIMI Study Group, Associate Professor of Medicine)","doi":"10.1016/S1098-3597(07)80025-1","DOIUrl":"10.1016/S1098-3597(07)80025-1","url":null,"abstract":"<div>Cardiovascular disease (CVD) is the leading cause of death in the United States and many parts of the world. Potentially modifiable risk factors for CVD include tobacco use, physical inactivity, hypertension, elevated low-density lipoprotein cholesterol, and a cluster of interrelated metabolic risk factors. Over the last several decades, efforts to prevent or treat CVD risk factors have resulted in significantly lower rates of CVD-related mortality. However, many patients never achieve adequate control of CVD risk factors even when these factors have been identified. In addition, the growing prevalence of obesity and type 2 diabetes mellitus (DM) threatens to undermine the improvements in CVD that have been achieved. In the United States, approximately two thirds of adults are overweight or obese, and even modest excess body weight is associated with a significantly increased risk of CVD-related mortality. Lifestyle interventions to promote weight loss reduce the risk of CVD-related illness but are difficult for patients to sustain over long periods of time. The increased incidence of obesity has also contributed to significant increases in the prevalence of other important CVD risk factors, including hypertension, dyslipidemia, insulin resistance, and type 2 DM. Pharmacologic therapies are currently available to address individual CVD risk factors, and others are being evaluated, including endocannabinoid receptor antagonists, inhibitors of peroxisome proliferator-activated receptor subtypes alpha and gamma, and several agents that modulate the activity of glucagon-like peptide-1. The new agents have the potential to significantly improve several CVD risk factors with a single medication and may provide clinicians with several new strategies to reduce the long-term risk of CVD.</div>","PeriodicalId":80265,"journal":{"name":"Clinical cornerstone","volume":"8 3","pages":"Pages 11-28"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1098-3597(07)80025-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27418320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 152

CME test answers cardiometabolic risk and risk management CME测试回答心脏代谢风险和风险管理

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2008-04-29 DOI: 10.1016/S1098-3597(07)80034-2

引用次数: 0

Managing Hyperglycemia in Hospitalized Patients 住院患者高血糖的处理

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2009-05-03 DOI: 10.1016/S1098-3597(09)60007-7

Susan S. Braithwaite MD , Hetal P. Mehrotra RD, MHA, CPHQ , Beverly Robertson MPH, MT (ASCP) , Linda M. McElveen BSN, RN, CRNI , Cara L. Thompson MSN, APRN, BC-ADM, CDE

{"title":"Managing Hyperglycemia in Hospitalized Patients","authors":"Susan S. Braithwaite MD , Hetal P. Mehrotra RD, MHA, CPHQ , Beverly Robertson MPH, MT (ASCP) , Linda M. McElveen BSN, RN, CRNI , Cara L. Thompson MSN, APRN, BC-ADM, CDE","doi":"10.1016/S1098-3597(09)60007-7","DOIUrl":"10.1016/S1098-3597(09)60007-7","url":null,"abstract":"<div>Insulin infusion is used in the critical care setting for prevention of hyperglycemia and is administered most safely under a structured, dynamic, dose-defining algorithm. The ordering of basal-prandial-correction SC insulin therapy, appropriate for most hospitalized patients who are eating, is simplified and standardized to excellence by the development of institutional order sets or computerized order entry templates. Basal insulin therapy is prescribed as intermediate-acting insulin or long-acting insulin analogue. Prandial insulin therapy is delivered with meals to prevent excessive glycemic excursions from occurring after ingestion of meals and is prescribed as rapid-acting insulin analogue. Correction-dose insulin therapy is ordered as small doses of rapid-acting insulin analogue delivered to correct hyperglycemia and is prescribed with appropriate timing so as to avoid stacking with previously administered doses of rapid-acting insulin analogue. Patients knowledgeable in diabetes self-management will experience satisfaction under an institutional policy that allows self-management to continue under appropriate conditions during hospitalization. To craft appropriate institutional tools for patient care, the input and consensus of a multidisciplinary group of health care professionals, including primary care providers and hospitalists, as well as specialists in diabetes with backgrounds in endocrinology, nutrition and dietetics, nursing, pharmacy, laboratory sciences, and quality assurance, is required.</div>","PeriodicalId":80265,"journal":{"name":"Clinical cornerstone","volume":"8 2","pages":"Pages 44-57"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1098-3597(09)60007-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27335740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

CME Information 芝加哥商品交易所的信息

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2009-05-03 DOI: 10.1016/S1098-3597(09)60002-8

引用次数: 0